Clearmind submits FDA recommendations on psychedelic therapies
Clearmind says it is advancing dialogue with the U.S. federal government on psychedelic therapies and submitting recommendations to the FDA. (More details to follow.)
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Clearmind submits FDA recommendations on psychedelic therapies
Clearmind Medicine says it advanced dialogue with U.S. federal government on psychedelic therapies and submitted recommendations to the FDA, calling for new regulatory pathways and cost savings via non-hallucinogenic neuroplastogens for alcohol use disorder.